Abstract: A method for drivable area detection and autonomous obstacle avoidance of unmanned haulage equipment in deep confined spaces is disclosed, which includes the following steps: acquiring 3D point cloud data of a roadway; computing a 2D image drivable area of the coal mine roadway; acquiring a 3D point cloud drivable area of the coal mine roadway; establishing a 2D grid map and a risk map, and performing autonomous obstacle avoidance path planning by using an improved particle swarm path planning method designed for deep confined roadways; and acquiring an optimal end point to be selected of a driving path by using a greedy strategy, and enabling an unmanned auxiliary haulage vehicle to drive according to the optimal end point and an optimal path.

Abstract: A therapeutic hydrogel material is disclosed for the delivery of CAR-T cells that allows their distribution in the tumor resection recess, cavity, or void in combination with platelets decorated with the anti-programmed death-ligand 1 (PDL1) blocking antibody (aPDL1). The delivered hydrogel material acts as a reservoir for both CAR-T cells and platelet-bound aPDL1. Furthermore, inflammation occurring during the surgical wound healing triggers the release of platelet-derived microparticles containing the aPDL1. Cells delivered by the engineered hydrogel show significant control of local and distant tumor recurrence without causing toxic effects. In some embodiments, nanoparticles containing cytokines are also loaded in the therapeutic hydrogel material to maintain the activity and proliferation ability of CAR-T cells.

Abstract: Disclosed are a duplexer, a network device, a control method, an electronic device and a storage medium. The duplexer may include: a filter, a dielectric tuning component; and a control module connected with the dielectric tuning component and configured to control a relative position between the dielectric tuning component and the filter to adjust an operating frequency of the duplexer.

Abstract: A therapeutic hybrid microneedle patch mimics the inherent counter-regulatory effects of ?-cells and ?-cells for blood glucose management by dynamically releasing insulin or glucagon contained within the microneedles of the therapeutic hybrid microneedle patch. The two types of microneedles in the therapeutic hybrid microneedle patch share a co-polymerized matrix but comprise different ratios of the key monomers to be ‘dually-responsive’ to both hyper- and hypoglycemic glucose conditions. In a type 1 diabetic mouse model, the therapeutic hybrid microneedle patch effectively controls hyperglycemia while minimizing the occurrence of hypoglycemia in the setting of insulin therapy and simulated delayed meal or insulin overdose. In other embodiments, multiple patches are applied to achieve similar results.

Abstract: A retinoic acid modified lysosome targeting chimera (LYTAC) molecule, a preparation method and applications thereof are provided. A structural formula of the retinoic acid modified LYTAC molecule is shown as following Formula I, in which, n represents a molecular weight of polyethylene glycol (PEG), n is in a range of 60 to 5000, R is one of an antibody, a polypeptide and a micromolecule compound targeting a targeted protein. The retinoic acid modified LYTAC molecule can be applied to targeted protein degradation and preparation of tumor cell activity inhibitors. Retinoic acid has high biosafety, is easy to obtain and modify, can be coupled with any antibody, polypeptide or micromolecule that targets the binding protein receptor to realize lysosomal degradation of extracellular or membrane proteins, can be used to prepare tumor cell activity inhibitors and to treat tumors, inflammation and other diseases, and has a broad application prospect.

Abstract: Chimeric antigen receptor T cells (CAR T) therapy reached a milestone in eradicating B-cell malignancies, but beneficial effects in solid tumors are not obtained yet. A porous microneedle patch is disclosed that carries CAR T cells to solid tumors (or other cell types). The device is a honeycomb-like porous microneedle patch that accommodates CAR T cells and allows in situ penetration-media seeding of CAR T cells within post-surgical resection of solid tumors. CAR T cells loaded in the pores of the microneedle tips were readily escorted to the tumor in an evenly scattered manner without losing their activity. Such microneedle-mediated local delivery enhanced infiltration and immune stimulation of CAR T cells as compared to direct intratumoral injection. This tailorable patch offers a transformative platform for scattered seeding of living cells for treating a variety of diseases. Other cell types may be loaded into the porous microneedles.

Abstract: A method of updating a road information, an electronic device, and a storage medium, which relate to an artificial intelligence technology field, in particular to fields of computer vision, deep learning, big data, high-definition map, intelligent transportation, automatic driving and autonomous parking, cloud service, Internet of Vehicles and intelligent cabin technologies. The method includes: processing image data corresponding to a target road region to obtain a set of first road lines; obtaining a set of second road lines according to a trajectory map corresponding to the target road region; calibrating the set of first road lines by using the set of second road lines to obtain a set of third road lines; combining the set of third road lines and a set of historical road lines corresponding to the target road region to obtain a combination result; and updating the set of historical road lines according to the combination result.

Abstract: The method of treating obesity-induced glucose intolerance and liver fibrosis includes administering to a patient a therapeutically effective amount of a substance for inhibiting the Notch signaling pathway of the patient. The substance is formed from encapsulated ?-secretase inhibitor (GSI) nanoparticles. As a non-limiting example, each nanoparticle may be formed from a GSI, such as dibenzazepine (a bioavailable GSI) encapsulated in poly(lactic co-glycolic acid) (PLGA). The encapsulated GSI nanoparticles (GSI NPs) provide localized and effective inhibition of hepatic Notch signaling, thus improving obesity-induced glucose tolerance and liver fibrosis without intestinal side effects.

Abstract: A method for processing a map, an electronic device, and a storage medium, which relate to a technical field of computer technology, in particular to computer vision technology and high-definition map technology. The method includes: segmenting a first road line to obtain a plurality of first sub-road lines, wherein the first road line is obtained according to a segmentation mask for an image, and the image corresponds to a target region; segmenting a second road line to obtain a plurality of second sub-road lines, wherein the second road line is obtained according to a trajectory information corresponding to the target region; and determining a target road line according to first similarities between the plurality of first sub-road lines and the plurality of second sub-road lines.

Abstract: The present invention provides a semiconductor structure for forming a CMOS image sensor. The semiconductor structure includes at least a photodiode formed in the substrate for collecting photoelectrons, and the photodiode has a pinning layer, a first doped region and a second doped region in order from top to bottom in a height direction of the substrate. The semiconductor structure further includes a third doped region located in the substrate corresponding to a laterally extending region of the second doped region. The first doped region has an ion doping concentration greater than the ion doping concentration of the second doped region, the ion doping concentration of the second doped region is greater than the ion doping concentration of the third doped region, and the third doped region is in contact with the second doped region after diffusion. The present invention also provides a method of manufacturing the above-described semiconductor structure.

Abstract: Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.

Abstract: The disclosure discloses a global shutter CMOS image sensor, which adopts non-uniform storage diffusion region doping to reduce the junction leakage at storage points, so as to ensure that with the increase of the depth of photodiodes and the increase of pixels, all carriers in rows read subsequently can be transferred to storage diffusion regions, the loss of the carriers in the storage diffusion regions is not caused when a global shutter transistor is turned on, and the carriers can be completely transferred from the storage diffusion regions to floating diffusion regions through second transfer transistors even if the number of rows of pixel units increases during reading-out row by row. The disclosure further discloses a method for making the global shutter CMOS image sensor.

Abstract: A cold atmospheric plasma (CAP)-mediated ICB therapy/delivery device are disclosed herein that employs a patch having microneedles that are used to deliver the CAP transdermally along with an immune checkpoint inhibitor for enhancing transdermal treatment efficacy. The hollow-structured microneedle patch can facilitate the transportation of CAP through the skin, causing tumor cell death. The release of cancer antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating the T cell-mediated immune response. Anti-PDL1 antibody (aPDL1), an immune checkpoint inhibitor (or other immune checkpoint inhibitors), released from the microneedle patch (in some embodiments) further augments the anti-tumor immunity. The transdermal combinational CAP and ICB therapy inhibits tumor growth for both primary tumors as well as distant tumors, with prolonged survival in the tumor-bearing mice. Such results should translate to other species.

Abstract: Two-terminal resistive switching devices can have a switching layer in which a filament forms and deforms to varying degrees to represent distinct logical states. This switching layer can be formed having a varying ratio, X, of nitrogen to silicon at various strata of the switching layer. Such can result in a two-terminal memory device with improved stability and other characteristics.

Abstract: The present invention provides a semiconductor structure for forming a CMOS image sensor. The semiconductor structure includes at least a photodiode formed in the substrate for collecting photoelectrons, and the photodiode has a pinning layer, a first doped region and a second doped region in order from top to bottom in a height direction of the substrate. The semiconductor structure further includes a third doped region located in the substrate corresponding to a laterally extending region of the second doped region. The first doped region has an ion doping concentration greater than the ion doping concentration of the second doped region, the ion doping concentration of the second doped region is greater than the ion doping concentration of the third doped region, and the third doped region is in contact with the second doped region after diffusion. The present invention also provides a method of manufacturing the above-described semiconductor structure.

Abstract: Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.

Abstract: A composition comprising an amphiphilic polymeric material that is both hydrogen peroxide- and hypoxia-sensitive is described. The composition can further include a glucose-oxidizing enzyme and insulin, a bioactive derivative thereof, and/or another therapeutic agent (e.g., another diabetes treatment agent). The polymeric material can form vesicles that comprise single or multiple layers of the polymeric material that enclose the glucose-oxidizing enzyme and the insulin, bioactive derivative and/or other therapeutic agent. The vesicles can be loaded into microneedles to, for example, prepare microneedle arrays for skin patches. Methods of delivering insulin to a subject using the compositions, vesicles, microneedles, and/or microneedle array skin patches are also described.

Abstract: Disclosed are bioresponsive protein complexes comprising immune checkpoint blockade inhibitors and methods of their use.

Abstract: Disclosed are engineered particles comprising a photosensitizer and methods for treating cancer comprising administering the engineered particles and tumor-specific T cells to a subject, wherein the photosensitizer is stimulated by light comprising a wavelength that excites the photosensitizer.

Abstract: A closed-loop insulin delivery system is described. More particularly, the presently disclosed insulin delivery system can comprise glucose-responsive vesicles that release insulin in response to hypoxia triggered by enzymatic reduction of glucose. In addition or as an alternative to insulin, the delivery system can release other diabetes treatment agents, such as non-insulin-based diabetes treatment agents. The vesicles can be prepared from a hypoxia sensitive polymer, such as a hypoxia-sensitive hyaluronic acid (HS-HA). The HS-HA can comprise hydrophobic groups that can be reduced in hypoxic environments to form hydrophilic groups. The vesicles can be loaded into microneedles and microneedle array patches for use in the treatment of diabetes or to otherwise regulate blood glucose levels in subjects in need of such treatment.